Never Miss Important Company Updates Again
Get AI-powered summaries of SEC filings delivered to your inbox
Follow your favorite stocks and get email alerts when they release important updates. Completely free.
Passage Bio, Inc. is a clinical-stage genetic medicines company focused on developing one-time gene therapies for neurodegenerative diseases. Its lead candidate, PBFT02, targets conditions like frontotemporal dementia by delivering functional genes to the central nervous system. The company leverages AAV vectors, innovative delivery routes, and collaborations to address unmet medical needs in CNS disorders with a focus on safety, efficacy, and regulatory success.
This description was generated via AI from an annual report. Updated about 1 year ago.